Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

DRCR.net Protocol Review

By: R.V. Paul Chan, MD; Jorge A. Fortun, MD; Geeta A. Lalwani, MD; Andrew A. Moshfeghi, MD; Dante Pieramici, MD; Charles C. Wykoff, MD

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

This continuing medical education (CME) activity captures content from a roundtable meeting held in December 2015.

This certified CME activity is for retina specialists and general ophthalmologists involved in the management of patients with retinal disease.

Expiration Date: Sunday, April 30, 2017
Release Date: April 2016

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Discuss the ocular and systemic effects of anti-VEGF therapies in patients with diabetes and how to educate patients on appropriate expectations
  • Assess clinical studies involving new approaches to treat DME and proliferative diabetic retinopathy
  • Use expert case examples to differentiate between clinical study dosing protocols and alternative dosing schedules
  • Evaluate treatment options and develop a treatment regimen that can reduce patient burden and practice capacity

Accreditation and Designation Statement

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC, New Retina MD, and Retina Today. Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians. CREDIT

DESIGNATION STATEMENT

Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation.

Faculty and Disclosures

R.V. Paul Chan, MD, MSc, FACS
St. Giles associate professor of pediatric retina
Director of the retina service
Weill Cornell Medical College
Adjunct associate professor of ophthalmology
Columbia University College of Physicians and Surgeons
New York, New York

Jorge A. Fortun, MD
Assistant professor of ophthalmology
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine
Miami, Florida

Geeta A. Lalwani, MD
Vitreoretinal surgeon
Rocky Mountain Retina Associates
Boulder, Colorado

Andrew A. Moshfeghi, MD, MBA
Director of the clinical trials unit
Associate professor of ophthalmology
Keck School of Medicine, University of Southern California
Los Angeles, California

Dante J. Pieramici, MD
Partner in California Retina Consultants
Director of the California Retina Research Foundation
Santa Barbara, California

Charles C. Wykoff, MD, PhD
Co-director of research at Retina Consultants of Houston
Deputy chair of ophthalmology, Blanton Eye Institute, Houston Methodist Hospital
Houston, Texas

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, New Retina MD, Retina Today, or Regeneron Pharmaceuticals.

Policy on Privacy and Confidentiality

DISCLOSURE POLICY

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

R.V. Paul Chan, MD, MSc, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant: Alcon; Allergan; and Visumex.

Jorge A. Fortun, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Speaker: Alcon and ThromboGenics.

Geeta A. Lalwani, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Speaker: Genentech. Consultant: Allergan. Stock Holder: Ocugen.

Andrew A. Moshfeghi, MD, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant: Allergan; Genentech; and Regeneron. Grant/Research: Genentech and Regeneron.

Dante J. Pieramici, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Speaker: Allergan; Genentech; and ThromboGenics. Grant Research Support: Allergan; Genentech; Regeneron Pharmaceuticals; and Opthea.

Charles C. Wykoff, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant: Alcon; Alimera Sciences; Allergan; Bayer; Clearside Biomedica; DORC International; Genentech; ONL Therapeutics; Regeneron; and ThromboGenics. Speaker: Allergan and Regeneron. Grant Support: Acucela; Alcon; Allergan; Allegro; Ampio; Appellis Pharmaceutical; Clearside Biomedical; Genentech; Iconic Therapeutics; Ophthotech Corp; pSivida; Regeneron; Santen; ThromoGenics; and Xoma.

Cheryl Cavanaugh, MS, director of operations, Evolve; Emily Feinman, Retina Today; Michelle Dalton, medical writer; and Melanie Lawler, PhD, reviewer, have no financial relationships with commercial interests

 

OFF-LABEL STATEMENT

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DRCR.net Protocol Review

R.V. Paul Chan, MD; Jorge A. Fortun, MD; Geeta A. Lalwani, MD; Andrew A. Moshfeghi, MD; Dante Pieramici, MD; Charles C. Wycoff, MD

BackNext